GLP-1 regulates blood glucose levels through several mechanisms, including stimulation of glucose-dependent secretion of insulin, suppression of pancreatic glucagon release, satiety enhancement, delayed stomach emptying, and reduction of energy intake 7,8,9
Patients received the lowest effective dose and increases were only considered if they had stopped making progress
In this review, we review the evidence supporting combined SGLT2i and GLP-1RA therapy in type 2 diabetes with a focus on cardiometabolic outcomes, and we propose a pragmatic framework for clinical use
GLP-1s like semaglutide and tirzepatide are a key part of our Medically Supervised Weight Loss Program at Forum Health Las Colinas
The key difference lies in their mechanisms: Retatrutide activates three metabolic receptors (GIP, GLP-1, and glucagon) while Tirzepatide activates two (GIP and GLP-1)